Sarsasapogenin restores podocyte autophagy in diabetic nephropathy by targeting GSK3β signaling pathway

Podocyte injury following abnormal podocyte autophagy plays an indispensable role in diabetic nephropathy (DN), therefore, restoration of podocyte autophagy is considered as a feasible strategy for the treatment of DN. Here, we investigated the preventive effects of sarsasapogenin (Sar), the main active ingredient in Anemarrhena asphodeloides Bunge, on the podocyte injury in diabetic rats, and tried to illustrate the mechanisms underlying the effects in high glucose (HG, 40 mM)-treated podocytes (MPs). Diabetes model was established in rats with single streptozocin (60 mg. kg(-1)) intraperitoneal administration. The rats were then treated with Sar (20, 60 mg. kg(-1). i.g.) or a positive control drug insulin (INS) (40 U. kg(-1). d(-1), i.h.) for 10 weeks. Our results showed that both Sar and insulin precluded the decreases of autophagy-related proteins (ATG5, Beclin1 and LC3B) and podocyte marker proteins (podocin, nephrin and synaptopodin) in the diabetic kidney. Furthermore, network pharmacology was utilized to assess GSK3 beta as the potential target involved in the action of Sar on DN and were substantiated by significant changes of GSK3 beta signaling in the diabetic kidney. The underlying protection mechanisms of Sar were explored in HG-treated MPs. Sar (20, 40 mu M) or insulin (50 mU/L) significantly increased the expression of autophagy- related proteins and podocyte marker proteins in HG-treated MPs. Furthermore, Sar or insulin treatment efficiently regulated phosphorylation at activation and inhibition sites of GSK3 beta. To sum up, this study certifies that Sar meliorates experimental DN through targeting GSK3 beta signaling pathway and restoring podocyte autophagy.